MOVIN Pilot Randomized Controlled Trial (MOVIN)

Reproductive Mental Health of Ontario Virtual Intervention Network (MOVIN): A Pilot Randomized Controlled Trial

Despite available treatments for perinatal mood disorders, only 20% of affected women receive treatment that results in remission of symptoms. In order to address gaps in equitable access to treatment the investigators developed the Reproductive Mental health of Ontario Virtual Intervention Network (MOVIN), a virtual collaborative care platform to optimize access for pregnant and postpartum people in Ontario. MOVIN combines collaborative and stepped-care approaches to treatment of perinatal depression and anxiety. The overall objective of this pilot randomized controlled trial (RCT) is to determine the feasibility of implementing a protocol for studying MOVIN for pregnant and postpartum individuals with significant symptoms of depression and anxiety (EPDS > 12) in order to inform the conduct of a larger scale evaluation. O will be randomized to either the MOVIN or control condition and will be asked to complete follow-up assessments 12- and 24-weeks post-randomization. Participants in the MOVIN arm will receive access to the MOVIN platform which includes a care coordinator to help them navigate various virtual treatments. Participants in the control condition will receive a resource list and will navigate the various options on their own.

Study Overview

• Status: Completed
• Conditions: Depression, Postpartum
• Intervention / Treatment: Other: Enhanced Usual Care; Other: MOVIN Care Platform

Detailed Description

People with scores above 12 on the EPDS have a 10 times greater likelihood of having a diagnosis of depression than those with scores with 12 or less, so this is an appropriate cut-off. The primary endpoint is at 12 weeks post-randomization and the secondary endpoint is at 24 weeks post-randomization. Randomization will be performed as block randomization (varying block sizes) with a 1:1 allocation and will be stratified based on EPDS score (13-19 vs. 20 or greater). Participants who score 12 or less on the EPDS in their initial self-referral screen will be informed that they are not at high risk for having depressive or anxiety disorder and the current time, and can re-screen as needed. Participants whose score is in the 9-12 range (i.e. those who are not likely to be experiencing a depressive or anxiety disorder requiring mental health treatment, but might benefit from additional support) will receive an automated message that communicates their score and the acknowledgment of their possible need for support, and provides a list of resources in Ontario that may be helpful for them. These participants will be invited to re-screen at any time into the study, and will be asked permission to be re-contacted in future to determine which supports they used, if any.

• Study Type: Interventional
• Enrollment (Actual): 81
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5S1B2
      • Women's College Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion criteria:

1. Residents of Ontario at least 18 years of age
2. Currently pregnant or mother* of a live infant 0-12 months of age living at the same residence *through natural birth, adoption or surrogacy, including cis women, non-binary and transgender people in all their diversity
3. EPDS > 12
4. Registered with a primary care provider

Exclusion criteria:

1. Experiencing active suicidal ideation (MINI International Neuropsychiatric Interview)
2. Active substance use disorder (GAIN-SS), current mania or psychosis (MINI Neuropsychiatric Interview)
3. Unable to access the internet or a device that can support the MOVIN platform
4. Unable to participate in English
5. Unable to provide informed consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Enhanced Usual Care; Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.	Other: Enhanced Usual Care; A standardized handout with information on what treatment options might be useful to start with based on EPDS score and stage of pregnancy or postpartum.
Experimental: MOVIN; Enhanced Usual Care plus MOVIN Care Platform. The MOVIN Care Platform is virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.	Other: Enhanced Usual Care; A standardized handout with information on what treatment options might be useful to start with based on EPDS score and stage of pregnancy or postpartum.; Other: MOVIN Care Platform; Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of the trial protocol: Recruitment	Measures of recruitment and retention include rate of recruitment, reason for non-participation and rate of completion of follow-up measures.	12 weeks post randomization
Feasibility of the trial protocol: Acceptability	Measures of acceptability include participants' overall experience and satisfaction with and acceptance of the MOVIN platform and the care coordinator, the care coordinator's assessment of the MOVIN platform and its impact on patient care, and primary care providers' assessment of MOVIN's impact on patient care.	12 weeks post randomization
Feasibility of the trial protocol: Compliance	Measures of compliance include rate of completion of MOVIN-specific activities, rate of completion of suggested interventions, and rate of resource use.	12 weeks post randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of the trial protocol: Recruitment	Measures of recruitment and retention include rate of recruitment, reason for non-participation and rate of completion of follow-up measures.	24 weeks post randomization
Feasibility of the trial protocol: Acceptability	Measures of acceptability include participants' overall experience and satisfaction with and acceptance of the MOVIN platform and the care coordinator, the care coordinator's assessment of the MOVIN platform and its impact on patient care, and primary care providers' assessment of MOVIN's impact on patient care.	24 weeks post randomization
Feasibility of the trial protocol: Compliance	Measures of compliance include rate of completion of MOVIN-specific activities, rate of completion of suggested interventions, and rate of resource use.	24 weeks post randomization
Maternal clinical outcomes - depression symptoms	Depressive symptoms will be measured using the Edinburgh Postnatal Depressive Scale (EPDS), a self-report scale that has been validated for use in pregnancy and postpartum. EPDS scores range from 0 to 30. EPDS scores >12 are predictive of a diagnosis of depression, with higher scores indicating more severe symptoms.	12 and 24 weeks post randomization
Maternal clinical outcomes - anxiety symptoms	Anxiety symptoms will be measured using the General Anxiety Disorder-7 (GAD-7) scale, which is a self-report scale with good discriminate validity in perinatal populations. GAD-7 scores range from 0 to 21, with higher scores indicating more severe symptoms.	12 and 24 weeks post randomization
Maternal clinical outcomes - quality of life	Quality of life will be measured using the 5 Level-5 Dimension EuroQol 5 (EQ-5D-5L) which is a multi-attribute utility instrument for measuring quality-adjusted life year (QALY), a preference-based utility measure of health-related quality of life as perceived by the patient. It can define 3125 different health states ranging from 11111 (full health) to 55555 (worst health).	12 and 24 weeks post randomization
Health service use: participant time	Measured by participant self-report of activities related to attending appointments and obtaining services.	12 and 24 weeks post randomization
Health service use: participant cost	Measured by participant self-report of costs related to attending appointments and obtaining services.	12 and 24 weeks post randomization
Health service use: health system costs	Calculated from participant self-report of medical costs such as hospitalizations, visits with health professionals and medications.	12 and 24 weeks post randomization
Care coordinator time	Care coordinator time per participant will be measured as the time spent per participant on the MOVIN platform, time spent on phone assessments and other related activities.	12 and 24 weeks post randomization
Care coordinator cost	Care coordinator cost per participant will be measured as the cost per participant on the MOVIN platform, on phone assessments and other related activities.	12 and 24 weeks post randomization
Dyadic relationship	The Dyadic Adjustment Scale (DAS) is a self-report measure of relationship adjustment with an intimate partner and will be used to measure relationship distress. The first 15 items of the 32-item measure will be used to assess dyadic consensus. Scores range fro 0 to 75. Higher scores indicate a higher degree of dyadic consensus.	12 and 24 weeks post randomization
Maternal child relationship	All participants who are postpartum at any time point will complete Parenting Stress Index short form (PSI-SF) to measure parenting stress. This is a 36-item measure consisting of 3 sub-scales: parental distress, dysfunction in the parent-child relations and difficult child. Scores range from 36 to 180. Higher scores indicate higher levels of parenting stress.	12 and 24 weeks post randomization
Infant temperament	Infant temperament will be measured using the Infant Characteristics Questionnaire (ICQ), an instrument that assesses parental perceptions of difficult infant temperament. Scores range from 28 to 196. Higher scores indicate a higher level of parental perceptions of difficult infant temperament.	Baseline, 12 and 24 weeks post randomization

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Co-variates	We will collect sociodemographic, obstetrical and psychiatric history data. We will also conduct a diagnostic phone interview using the MINI International Neuropsychiatric Interview for major depressive disorder, obsessive-compulsive disorder, panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, alcohol and substance abuse, past (hypo)mania and psychosis, and post-traumatic stress disorder.	Baseline
Maternal birth outcomes	Self-reported pregnancy and birth complications, if applicable.	Baseline, 12 and 24 weeks post randomization
Neonatal birth outcomes	Self-reported neonatal birth outcomes including medical conditions and complications, if applicable.	Baseline, 12 and 24 weeks post randomization

Collaborators and Investigators

• Sponsor: Women's College Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 12, 2021
• Primary Completion (Actual): June 30, 2022
• Study Completion (Actual): December 30, 2022

Study Registration Dates

• First Submitted: December 7, 2020
• First Submitted That Met QC Criteria: December 17, 2020
• First Posted (Actual): December 23, 2020

Study Record Updates

• Last Update Posted (Actual): April 26, 2023
• Last Update Submitted That Met QC Criteria: April 24, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Mood Disorders; Pregnancy Complications; Puerperal Disorders; Depressive Disorder; Depression, Postpartum
• Other Study ID Numbers: 2020-0054-B

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No